



Somatuline[®] Depot
(lanreotide) Injection 120 mg

MAKE TODAY A TURNING POINT

ASK YOUR DOCTOR ABOUT SOMATULINE[®] DEPOT

LOOK INSIDE TO FIND OUT HOW SOMATULINE DEPOT TREATS
GASTROINTESTINAL AND PANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS)
AND CARCINOID SYNDROME

IMPORTANT SAFETY INFORMATION

- Do not take **SOMATULINE DEPOT** if you are allergic to lanreotide.
- **SOMATULINE DEPOT** may cause **serious side effects**, including:
 - Gallstones
 - Changes to your blood sugar (high or low blood sugar),
 - Slow heart rate, and
 - High blood pressure.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

 **IPSEN**
Innovation for patient care

WHAT ARE GEP-NETs?



GEP-NETs are **gastrointestinal and pancreatic neuroendocrine tumors**. They are a rare type of cancer that can occur in the pancreas and/or gastrointestinal tract.

It can take a while for doctors to diagnose GEP-NETs. That's because symptoms can mimic more common diseases and, in the early stages, there may be no symptoms at all.

- Sometimes GEP-NETs are detected during an unrelated scan or surgery for another condition
- Sometimes GEP-NETs aren't diagnosed until the disease has advanced. Tumors can't be completely removed through surgery but can still be treated with certain medications

What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

WHAT IS CARCINOID SYNDROME?

Carcinoid syndrome occurs when a neuroendocrine tumor **secretes certain chemicals** into your bloodstream. That causes signs and symptoms such as **diarrhea** and **flushing**.



Flushing is a redness of the skin that suddenly appears on the face, neck, and other parts of the body.



HOW COMMON ARE NETs?



About **12,000** people each year are diagnosed with **gastrointestinal, pancreatic, neuroendocrine, or carcinoid tumors** in the United States.

IMPORTANT SAFETY INFORMATION (continued)

- **Tell your healthcare provider (HCP) if you have any of the following symptoms:**
 - **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
 - **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



Somatuline[®] Depot

(pronounced So-mah-tu-leen Dee-Poh) is the

FIRST **AND** ONLY

FDA-approved treatment for adults both to slow the growth of gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs) that have spread or cannot be removed by surgery...and treat carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

SLOWS THE GROWTH OF TUMORS

In a clinical study,
Somatuline[®] Depot

**REDUCED THE RISK OF
DISEASE PROGRESSION
OR DEATH BY**

53%

versus placebo, in patients
whose disease had spread or
could not be removed by surgery

At 22 months, **more than half** of the patients taking Somatuline Depot lived longer without disease progression. At 16.6 months, half of the patients taking sterile injection placebo had their cancer progress.

IMPORTANT SAFETY INFORMATION (continued)

- **Tell your healthcare provider (HCP) if you have any of the following symptoms (continued):**
 - **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
 - **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.

ABOUT THE STUDY

Somatuline Depot was **studied for nearly 2 years** in adults with GEP-NETs that had spread or could not be removed by surgery. In some patients, the cancer started in their pancreas. In others, it started elsewhere such as in their intestinal tract, which includes the colon. There were **204 patients** in the study. Patients were divided into 2 groups, which received either Somatuline Depot 120 mg or placebo by deep subcutaneous injection every 4 weeks.



Talk to your doctor and see if
Somatuline Depot is right for you.



It is not known if Somatuline Depot is safe and effective in children.

**Please see Important Safety Information throughout, and
accompanying full Prescribing Information, including
Patient Information.**

TREATS CARCINOID SYNDROME

Somatuline[®] Depot is FDA-approved to treat adults with carcinoid syndrome to **reduce the need** for the use of short-acting somatostatin rescue therapy.

In a clinical study,
Somatuline Depot

**REDUCED THE USE
OF SHORT-ACTING
RESCUE THERAPY BY**

15%

versus placebo.

Short-acting rescue therapy is used to lessen symptoms of carcinoid syndrome, including diarrhea and flushing.

IMPORTANT SAFETY INFORMATION (continued)

• **The most common side effects of SOMATULINE DEPOT in people with:**

- **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
- **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



Talk to your doctor and see if Somatuline Depot is right for you.

A conversation on side effects is an important part of talking to your doctor about treatment options.

HOW DOES IT WORK?

Natural somatostatin helps to control the release of many different types of hormones. This hormone is found naturally in the human body.

Somatuline[®] Depot contains lanreotide, a synthetic, or **man-made, version of** somatostatin.

It's not known exactly how Somatuline Depot works in the body to:

- Delay the growth of GEP-NETs that have spread or cannot be removed by surgery
- Reduce the need for short-acting somatostatin medicine

IMPORTANT SAFETY INFORMATION (continued)

- SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.
- Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



The medicine reservoir is made up of tightly packed, microscopic nanotubes, which allows for the **low injection volume** of Somatuline Depot.



Somatuline Depot is slowly released into the bloodstream, which is why you can receive it **monthly**.

ONCE-MONTHLY INJECTION WITH A REDESIGNED SYRINGE

You will receive a Somatuline[®] Depot deep subcutaneous injection **every 4 weeks** administered by your healthcare provider.

To help the injection process during your visit, the Somatuline Depot syringe has been redesigned with a **sturdy grip and plunger** for the administering healthcare provider.

If you're already being treated with Somatuline Depot for GEP-NETs, **no additional dose** is needed to treat carcinoid syndrome. Your healthcare provider will tell you **how long** you need to receive Somatuline Depot.

Somatuline Depot is **injected deep under the skin of the upper outer area of your buttock**.

- Your injection site should alternate between your right and left buttock from one injection of Somatuline Depot to the next
- Remind your healthcare provider at your visit which side was previously injected



Visit [SomatulineDepot.com](https://www.somatuline.com)
to learn more



IMPORTANT SAFETY INFORMATION (continued)

- **Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:** have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE[®] DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.

Especially tell your HCP if you take:

- Insulin or other diabetes medicines,
- A cyclosporine (Gengraf, Neoral, or Sandimmune), or
- Medicines that lower your heart rate, such as beta blockers

Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.



It is not known if Somatuline Depot is safe and effective in children.

SUPPORT THROUGHOUT YOUR TREATMENT

IPSEN CARES[®] (Coverage, Access, Reimbursement & Education Support) program can help simplify the coverage and treatment process for you.

ELIGIBLE* PATIENTS CAN SAVE UP TO \$20,000 PER YEAR ON OUT-OF-POCKET COSTS

If **eligible**, you may receive up to \$20,000 in financial support throughout the calendar year, with no out-of-pocket responsibility for your prescription.

HOW TO ENROLL

Visit www.ipsencares.com and fill out an enrollment form or **ask your healthcare provider** to call IPSEN CARES[®].

QUESTIONS?

An IPSEN CARES[®] Patient Access Specialist is available to help you at **(866) 435-5677**, Monday through Friday, 8 AM to 8 PM ET, or visit www.ipsencares.com.

IPSEN CARES[®]
Coverage, Access, Reimbursement & Education Support

*Patient Eligibility & Terms and Conditions:

Patients are not eligible for copay assistance through IPSEN CARES[®] if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, "Government Programs"), or where prohibited by law. Patients residing in Massachusetts, Minnesota, Michigan, or Rhode Island can only receive assistance with the cost of Ipsen products but not the cost of related medical services (injection). Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year.

Cash-pay patients are eligible to participate. "Cash-pay" patients are defined for purposes of this program as patients without insurance coverage or who have commercial insurance that does not cover Somatuline[®] Depot. Medicare Part D enrollees who are in the prescription drug coverage gap (the "donut hole") are not considered cash-pay patients, and are not eligible for copay assistance through IPSEN CARES[®]. For patients with commercial insurance who are not considered to be cash-pay patients, the maximum copay benefit amount per prescription is an amount equal to the difference between the annual maximum copay benefit of \$20,000 and the total amount of copay benefit provided to the patient in the Somatuline[®] Depot Copay Program. For cash-pay patients, the maximum copay benefit amount per prescription is \$1,666.66, subject to the annual maximum of \$20,000 in total. Patient pays any amount greater than the maximum copay savings amount per prescription.

Patient or guardian is responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, or Health Reimbursement Account. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or RxCrossroads by McKesson, are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

What is SOMATULINE[®] DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

- **Do not take SOMATULINE DEPOT** if you are allergic to lanreotide.
- **SOMATULINE DEPOT may cause serious side effects**, including:
 - **Gallstones**
 - **Changes to your blood sugar (high or low blood sugar),**
 - **Slow heart rate,** and
 - **High blood pressure.**
- **Tell your healthcare provider (HCP) if you have any of the following symptoms:**
 - **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
 - **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.

- **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
- **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.
- **The most common side effects of SOMATULINE DEPOT in people with:**
 - **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
 - **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs
- SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.
- Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.

IMPORTANT SAFETY INFORMATION (continued)

- **Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:** have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.
- **Tell your HCP about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.
- **Especially tell your HCP if you take:**
 - Insulin or other diabetes medicines,
 - A cyclosporine (Gengraf, Neoral, or Sandimmune), or
 - Medicines that lower your heart rate, such as beta blockers.Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full **Prescribing Information**, including **Patient Information**.



Visit SomatulineDepot.com
to learn more



SOMATULINE[®] DEPOT

**SLOWS THE GROWTH
OF TUMORS**

**TREATS CARCINOID
SYNDROME**

**HAS A REDESIGNED
SYRINGE**

What is SOMATULINE[®] DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

Please see Important Safety Information throughout, and accompanying full **Prescribing Information**, including **Patient Information**.

Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.

IPSEN CARES is a registered trademark of Ipsen S.A.

©2020 Ipsen Biopharmaceuticals, Inc. June 2020. SMD-US-004149